Drug Type CIK therapy |
Synonyms CD38KO NK cell therapy, FC21-NK cell therapy, K NK 003 + [1] |
Target- |
Mechanism Immunologic cytotoxicity, Natural killer cell replacements |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Myeloid Leukemia | Phase 2 | US | 13 May 2020 | |
Myelodysplastic Syndromes | Phase 1 | US | 14 May 2020 |